rate and OS under the chemotherapy ± interferon-α proved to be inferior to those with PV
and CML.
Conclusions: The quantitative detection of BCR-ABL gene p210, p190 transcripts and JAK2
V617F, MPL mutations for diagnosis and monitoring of CMPN boosts personalization of
patient's management. The personalization of management of CMPN patients by the
administration of targeted therapy significantly increased the short- and long-term results of
treatment regardless the age and gender.